Literature DB >> 12486431

Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

Kristian Wachtell1, Björn Dahlöf, Jens Rokkedal, Vasilious Papademetriou, Markku S Nieminen, Gunnar Smith, Eva Gerdts, Kurt Boman, Jonathan N Bella, Richard B Devereux.   

Abstract

BACKGROUND: Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear.
METHODS: Two-dimensional and M-mode echocardiograms were recorded at baseline in 853 unmedicated patients with stage II to III hypertension and LV hypertrophy determined by electrocardiography (Cornell voltage duration > or =2440 mV x ms or modified Sokolow-Lyon criteria: SV1 + RV5/RV6 >38 mV) after 14 days of placebo treatment. Follow-up echocardiography was done after 1 year of blinded treatment with either losartan or atenolol, in some cases supplemented with thiazide and calcium antagonist to reach target a BP of 140/90 mm Hg.
RESULTS: Baseline systolic/diastolic BP were reduced from 174 +/- 20/95 +/- 11 to 151 +/- 19/84 +/- 11 mm Hg. LV mass was reduced from 234 +/- 56 to 207 +/- 51 g and relative wall thickness from 0.41 +/- 0.07 to 0.38 +/- 0.06 (all P <.001). Prevalence of concentric LV hypertrophy decreased from 24% to 6%, eccentric LV hypertrophy from 46% to 37%, and concentric LV remodeling from 10% to 6%; normal geometry increased from 20% to 51%. A shift toward lower LV mass and relative wall thickness was found, as approximately 73% of those with concentric LV remodeling at baseline shifted to normal geometric pattern, whereas only 7% of those with normal pattern at baseline shifted to concentric LV remodeling. Of patients with concentric LV hypertrophy at baseline, 34% shifted to eccentric LV hypertrophy, whereas only 3% with eccentric LV hypertrophy at baseline had concentric LV hypertrophy. Furthermore, multiple regression analysis showed that Doppler stroke volume reduction was a significant correlate of LV mass reduction (beta = 0.108, P <.001) independent of BP, heart rate change, and assigned drug treatment.
CONCLUSIONS: Antihypertensive treatment reduces LV mass and decreases the prevalence of LV hypertrophy and concentric LV remodeling. Additional control of Doppler stroke volume potentiates the effect of BP reduction on LV mass regression independent of the BP reduction per se.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486431     DOI: 10.1067/mhj.2002.126113

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

Review 1.  Evolving concepts in left ventricular systolic and diastolic remodeling: implications for therapy.

Authors:  W H Wilson Tang; Gary S Francis
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

Review 2.  Influence of Physical Activity on Hypertension and Cardiac Structure and Function.

Authors:  Sheila M Hegde; Scott D Solomon
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

Review 3.  Alterations in cardiac structure and function in hypertension.

Authors:  Mário Santos; Amil M Shah
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

4.  The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Jayashri Aragam; Michael R Zile; Susan Cheng; Emelia J Benjamin; Ramachandran S Vasan
Journal:  JACC Cardiovasc Imaging       Date:  2014-08-13

Review 5.  Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy.

Authors:  Chike C Nwabuo; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2020-02-03       Impact factor: 5.369

6.  Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity.

Authors:  Carolyn S P Lam; Jasmine Grewal; Barry A Borlaug; Steve R Ommen; Garvan C Kane; Robert B McCully; Patricia A Pellikka
Journal:  Hypertension       Date:  2010-03-09       Impact factor: 10.190

Review 7.  [Cardiovascular end organ impairment due to hypertension].

Authors:  C M Schannwell; S Steiner; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

8.  Sokolow-Lyon voltage is suitable for monitoring improvement in cardiac function and prognosis of patients with idiopathic dilated cardiomyopathy.

Authors:  Kenji Fukaya; Kyosuke Takeshita; Takahiro Okumura; Hiroaki Hiraiwa; Soichiro Aoki; Takeo Ichii; Yuki Sugiura; Katsuhide Kitagawa; Toru Kondo; Naoki Watanabe; Naoaki Kano; Kenji Furusawa; Akinori Sawamura; Ryota Morimoto; Yasuko Bando; Toyoaki Murohara
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-02-03       Impact factor: 1.468

Review 9.  [Hypertension and cardiac failure].

Authors:  C M Schannwell; M G Hennersdorf; B E Strauer
Journal:  Internist (Berl)       Date:  2007-09       Impact factor: 0.743

10.  Multiple pheochromocytomas and paragangliomas in a young patient carrying a SDHD gene mutation.

Authors:  Astrid Novosel; Alfred Heger; Peter Lohse; Heinrich Schmidt
Journal:  Eur J Pediatr       Date:  2004-12       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.